Provided by Tiger Trade Technology Pte. Ltd.

Annexon, Inc.

5.61
-0.0200-0.36%
Pre-market: 5.610.00000.00%06:00 EST
Volume:3.35M
Turnover:18.85M
Market Cap:810.90M
PE:-4.04
High:5.79
Open:5.70
Low:5.57
Close:5.63
52wk High:7.18
52wk Low:1.29
Shares:144.55M
Float Shares:128.00M
Volume Ratio:1.77
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3871
EPS(LYR):-1.0058
ROE:-83.99%
ROA:-44.95%
PB:5.02
PE(LYR):-5.58

Loading ...

Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed?

Simply Wall St.
·
Jan 19

Annexon Grants Stock Options to New Employees Under Inducement Award Plan

Reuters
·
Jan 17

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 17

Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Jazz Pharmaceuticals (JAZZ) and Annexon Biosciences (ANNX)

TIPRANKS
·
Jan 16

Alpha Buying: Managing Biotech Risk With Insider Clues

Benzinga_recent_news
·
Jan 16

Annexon Highlights Late-Stage C1q Pipeline and 2026 Outlook

TIPRANKS
·
Jan 15

Annexon highlights its 2026 strategic priorities

TIPRANKS
·
Jan 12

Annexon Biosciences outlines pivotal 2026 milestones and outlook

TIPRANKS
·
Jan 12

Annexon Inc - Strong Financial Position Funds Operations Into Late 2027

THOMSON REUTERS
·
Jan 12

Annexon Inc - Proof-of-Concept Data for Anx1502 Expected in 2026

THOMSON REUTERS
·
Jan 12

Annexon Files Marketing Authorization Application for Tanruprubart in Europe

Reuters
·
Jan 12

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

GlobeNewswire
·
Jan 12

TD Cowen Keeps Their Buy Rating on Annexon Biosciences (ANNX)

TIPRANKS
·
Jan 09

Annexon Submits Tanruprubart Marketing Application to EMA for Guillain-Barré Syndrome

Reuters
·
Jan 08

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-BarrÉ Syndrome

THOMSON REUTERS
·
Jan 08

Annexon Inc: Bla Submission With U.S./European Data From Forward Trial Planned in 2026

THOMSON REUTERS
·
Jan 08

Annexon Initiated at Buy by Chardan Capital

Dow Jones
·
Dec 23, 2025

Chardan Initiates Annexon at Buy With $16 Price Target

MT Newswires Live
·
Dec 23, 2025

Annexon Grants Stock Options to New Employee Under Inducement Award Plan

Reuters
·
Dec 17, 2025

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 17, 2025